DexCom Company Profile (NASDAQ:DXCM)

About DexCom (NASDAQ:DXCM)

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

Industry, Sector and Symbol:

Sector: Medical
Industry: Medical Equipment, Supplies & Distribution
Sub-Industry: Health Care Equipment
Symbol: NASDAQ:DXCM
CUSIP: 25213110
Web: www.dexcom.com

Capitalization:

Market Cap: $3.88 billion
Outstanding Shares: 86,561,000

Average Prices:

50 Day Moving Avg: $60.25
200 Day Moving Avg: $69.73
52 Week Range: $42.62 - $88.80

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -111.95
P/E Growth: -1.61

Sales & Book Value:

Annual Revenue: $632.7 million
Price / Sales: 6.13
Book Value: $4.09 per share
Price / Book: 10.95

Profitability:

EBITDA: ($63,300,000.00)
Net Margins: -10.27%
Return on Equity: -27.90%
Return on Assets: -16.20%

Debt:

Debt-to-Equity Ratio: 0.91%
Current Ratio: 6.25%
Quick Ratio: 5.84%

Misc:

Average Volume: 2.00 million shs.
Beta: 0.33
Short Ratio: 9.13

Frequently Asked Questions for DexCom (NASDAQ:DXCM)

What is DexCom's stock symbol?

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) announced its quarterly earnings data on Tuesday, August, 1st. The company reported ($0.16) EPS for the quarter, beating the Zacks' consensus estimate of ($0.23) by $0.07. The firm earned $170.60 million during the quarter, compared to analysts' expectations of $166.54 million. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The company's revenue for the quarter was up 24.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.24) earnings per share. View DexCom's Earnings History.

When will DexCom make its next earnings announcement?

DexCom is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for DexCom.

Where is DexCom's stock going? Where will DexCom's stock price be in 2017?

20 analysts have issued 1 year target prices for DexCom's stock. Their predictions range from $49.50 to $95.00. On average, they anticipate DexCom's share price to reach $72.19 in the next twelve months. View Analyst Ratings for DexCom.

What are analysts saying about DexCom stock?

Here are some recent quotes from research analysts about DexCom stock:

1. According to Zacks Investment Research, "DexCom reported narrower-than-expected loss in the second quarter. We believe the company’s margins will continue to be under pressure in the coming quarters, owing to high product development costs and rising expenditures on research & development. Specifically, the company is expected to have lower margins on transmitter sales (in spite of the cost reduction initiatives). Additionally, cutthroat competition in the market for blood glucose monitoring devices is a major headwind. In the past one year, DexCom has underperformed the broader industry in terms of price. On the positive side, the glucose monitoring market represents significant commercial opportunity for DexCom. The company has also signed collaborative agreements with several companies, which should not only bring in cash, but also help expand its product portfolio." (10/17/2017)
2. Jefferies Group LLC analysts commented, "DXCM reported 4Q sales $3mn ahead of its pre-announcement. Guidance for 2017 remained +25-30% ($710-740mn); importantly, this considers competitive entries by MDT (670G) and ABT (Libre), but does not factor in any contribution from DXCM patients covered by Medicare. With this low bar set for 2017, the next-gen G6 and the Verily Type 2 system coming in 2018, DXCM remains well positioned to succeed in an evolving diabetes landscape. The stock remains a top idea." (3/1/2017)

Who are some of DexCom's key competitors?

Some companies that are related to DexCom include West Pharmaceutical Services (WST), Bio-Rad Laboratories (BIO), Hill-Rom Holdings (HRC), VWR Corporation (VWR), Integra LifeSciences Holdings Corporation (IART), ICU Medical (ICUI), LivaNova PLC (LIVN), Neogen Corporation (NEOG), NuVasive (NUVA), Nevro Corp. (NVRO), Haemonetics (HAE), Halyard Health (HYH), Inogen (INGN), CONMED Corporation (CNMD), MiMedx Group (MDXG), Asante Solutions (PUMP), OraSure Technologies (OSUR) and Orthofix International N.V. (OFIX).

Who are DexCom's key executives?

DexCom's management team includes the folowing people:

Terrance H. Gregg, Executive Chairman of the Board
Kevin R. Sayer, President, Chief Executive Officer, Director
Quentin S. Blackford, Chief Financial Officer
Donald Abbey, Executive Vice President, Quality and Information Technology
Andrew K. Balo, Executive Vice President - Clinical, Regulatory and Quality
Richard B. Doubleday, Executive Vice President, Chief Commercial Officer
Steven R. Pacelli, Executive Vice President - Strategy and Corporate Development
Heather Ace, Senior Vice President, Human Resources
Jake Leach, Senior Vice President of Research and Development
Jeffrey C. Moy, Senior Vice President - Operations

Who owns DexCom stock?

DexCom's stock is owned by a number of of institutional and retail investors. Top institutional investors include JANUS HENDERSON GROUP PLC (10.20%) and Eqis Capital Management Inc. (0.02%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Jess Roper, John Lister, Jonathan T Md Lord, Jorge A Valdes, Kevin R Sayer, Mark G Foletta, Richard Doubleday, Steven Robert Pacelli and Terrance H Gregg. View Institutional Ownership Trends for DexCom.

Who bought DexCom stock? Who is buying DexCom stock?

DexCom's stock was acquired by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. View Insider Buying and Selling for DexCom.

How do I buy DexCom stock?

Shares of DexCom can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is DexCom's stock price today?

One share of DexCom stock can currently be purchased for approximately $44.78.

MarketBeat Community Rating for DexCom (NASDAQ DXCM)

Community Ranking:		3.4 out of 5 ( )
Outperform Votes:		526 (Vote Outperform)
Underperform Votes:		255 (Vote Underperform)
Total Votes:		781

MarketBeat's community ratings are surveys of what our community members think about DexCom and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for DexCom (NASDAQ:DXCM) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	7 Hold Ratings, 13 Buy Ratings
Consensus Rating:	Buy (Score: 2.65)
Consensus Price Target:	$72.19 (61.22% upside)

Consensus Price Target History for DexCom (NASDAQ:DXCM)

Analysts' Ratings History for DexCom (NASDAQ:DXCM)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
10/4/2017	Wedbush	Reiterated Rating	Buy	$76.00	Low
9/29/2017	Leerink Swann	Reiterated Rating	Buy	$85.00 -> $57.00	High
9/29/2017	Raymond James Financial, Inc.	Downgrade	Outperform -> Mkt Perform		High
9/28/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$87.00	High
9/28/2017	Stephens	Reiterated Rating	Buy	$83.00 -> $70.00	High
9/28/2017	Barclays PLC	Reiterated Rating	Equal Weight	$76.00 -> $60.00	High
9/28/2017	Oppenheimer Holdings, Inc.	Lower Price Target	Outperform	$92.00 -> $85.00	High
9/28/2017	Robert W. Baird	Lower Price Target	Neutral -> Neutral	$79.00 -> $58.00	High
9/28/2017	Northland Securities	Downgrade	Outperform -> Market Perform	$85.00 -> $60.00	High
9/28/2017	Cowen and Company	Lower Price Target	Outperform	$90.00 -> $64.00	High
9/28/2017	BMO Capital Markets	Reiterated Rating	Outperform	$90.00 -> $62.00	High
9/28/2017	Canaccord Genuity	Reiterated Rating	Buy	$90.00 -> $69.00	High
9/28/2017	Jefferies Group LLC	Reiterated Rating	Buy	$91.00	High
9/28/2017	Citigroup Inc.	Downgrade	Outperform -> Market Perform		High
9/28/2017	J P Morgan Chase & Co	Downgrade	Overweight -> Neutral	$93.00 -> $71.00	High
5/7/2017	B. Riley	Reiterated Rating	Buy	$95.00	High
5/3/2017	BTIG Research	Downgrade	Buy -> Neutral		High
4/27/2017	William Blair	Reiterated Rating	Outperform		Low
4/4/2017	Royal Bank Of Canada	Reiterated Rating	Outperform	$87.00	Medium
3/1/2017	Northcoast Research	Reiterated Rating	Buy		N/A
1/3/2017	Morgan Stanley	Downgrade	Overweight -> Equal Weight	$87.00 -> $66.00	N/A
9/16/2016	Desjardins	Upgrade	Hold -> Buy		N/A
8/3/2016	Benchmark Co.	Lower Price Target	Buy	$106.00 -> $86.00	N/A
7/15/2016	Deutsche Bank AG	Boost Price Target	Buy	$90.00 -> $98.00	N/A

(Data available from 10/20/2015 forward)

Earnings History for DexCom (NASDAQ:DXCM)

Earnings by Quarter for DexCom (NASDAQ:DXCM)

Earnings History by Quarter for DexCom (NASDAQ DXCM)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
10/30/2017		($0.15)					N/A
8/1/2017	Q2 2017	($0.23)	($0.16)	$166.54 million	$170.60 million	View	Listen
5/2/2017	Q1 2017	($0.55)	($0.49)	$143.94 million	$142.30 million	View	Listen
2/28/2017	Q416	($0.10)	($0.09)	$167.51 million	$171.20 million	View	Listen
11/1/2016	Q316	($0.14)	($0.22)	$146.09 million	$148.60 million	View	N/A
8/2/2016	Q216	($0.12)	($0.24)	$132.48 million	$137.30 million	View	N/A
4/27/2016	Q116	($0.20)	($0.23)	$110.37 million	$116.20 million	View	Listen
2/23/2016	Q415	$0.01	$0.02	$122.93 million	$130.80 million	View	Listen
11/4/2015	Q315	($0.01)	($0.07)	$97.47 million	$105.20 million	View	N/A
8/5/2015	Q215	($0.03)	($0.05)	$84.74 million	$93.20 million	View	N/A
4/29/2015	Q115	($0.11)	($0.17)	$71.32 million	$72.80 million	View	N/A
2/25/2015	Q414	($0.03)	$0.02	$79.65 million	$84.30 million	View	N/A
11/6/2014	Q314	($0.05)	($0.08)	$60.20 million	$67.90 million	View	N/A
8/6/2014	Q214	($0.10)	($0.10)	$52.45 million	$58.80 million	View	Listen
5/1/2014	Q114	($0.08)	($0.17)	$44.15 million	$47.10 million	View	Listen
2/20/2014	Q413	($0.07)	($0.04)	$48.53 million	$51.30 million	View	Listen
11/6/2013	Q313	($0.13)	($0.09)	$35.90 million	$42.90 million	View	N/A
8/7/2013	Q2 2013	($0.16)	($0.14)	$31.14 million	$35.80 million	View	N/A
5/1/2013	Q1 2013	($0.17)	($0.16)	$28.26 million	$29.60 million	View	N/A
2/21/2013	Q4 2012	($0.15)	($0.12)	$31.09 million	$33.30 million	View	N/A
11/1/2012	Q312	($0.22)	($0.25)	$23.14 million	$23.10 million	View	N/A
8/6/2012		($0.20)	($0.21)			View	N/A
5/2/2012		($0.19)	($0.21)			View	N/A
2/23/2012		($0.17)	($0.18)			View	N/A
11/2/2011		($0.15)	($0.20)			View	N/A
8/3/2011		($0.11)	($0.11)			View	N/A
5/3/2011		($0.19)	($0.19)			View	N/A
3/3/2011		($0.19)	($0.16)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for DexCom (NASDAQ:DXCM)

2017 EPS Consensus Estimate: ($0.73)
2018 EPS Consensus Estimate: $0.04

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	8	($0.68)	($0.19)	($0.53)
Q2 2017	8	($0.28)	($0.12)	($0.19)
Q3 2017	8	($0.18)	$0.06	($0.10)
Q4 2017	8	($0.09)	$0.31	$0.09
Q1 2018	4	($0.21)	($0.06)	($0.14)
Q2 2018	4	($0.06)	$0.05	($0.02)
Q3 2018	4	($0.03)	$0.15	$0.05
Q4 2018	4	$0.00	$0.28	$0.15

(Data provided by Zacks Investment Research)

Dividend History for DexCom (NASDAQ:DXCM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for DexCom (NASDAQ:DXCM)

Insider Ownership Percentage: 1.70%

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Insider Trades by Quarter for DexCom (NASDAQ:DXCM)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/25/2017	Steven Robert Pacelli	EVP	Sell	1,450	$69.81	$101,224.50
9/20/2017	Kevin R. Sayer	CEO	Sell	6,000	$69.34	$416,040.00
9/11/2017	Andrew K. Balo	EVP	Sell	3,244	$72.27	$234,443.88
8/23/2017	Richard Doubleday	EVP	Sell	1,635	$75.26	$123,050.10
8/11/2017	Kevin R. Sayer	CEO	Sell	6,000	$69.77	$418,620.00
8/10/2017	Andrew K. Balo	EVP	Sell	3,244	$71.18	$230,907.92
7/24/2017	Steven Robert Pacelli	EVP	Sell	1,450	$69.47	$100,731.50
7/12/2017	Kevin R. Sayer	CEO	Sell	6,000	$71.86	$431,160.00
7/10/2017	Andrew K. Balo	EVP	Sell	3,200	$71.55	$228,960.00
6/23/2017	Steven Robert Pacelli	EVP	Sell	1,450	$78.19	$113,375.50
6/12/2017	Andrew K. Balo	EVP	Sell	3,200	$69.06	$220,992.00
6/12/2017	Kevin R. Sayer	CEO	Sell	6,000	$69.07	$414,420.00
5/23/2017	Richard Doubleday	EVP	Sell	3,182	$68.29	$217,298.78
5/17/2017	Kevin R Sayer	CEO	Sell	8,649	$68.39	$591,505.11
5/10/2017	Andrew K. Balo	EVP	Sell	3,200	$71.93	$230,176.00
4/24/2017	Richard Doubleday	EVP	Sell	3,182	$75.78	$241,131.96
4/20/2017	Terrance H Gregg	Insider	Sell	15,000	$74.10	$1,111,500.00
4/17/2017	Kevin R Sayer	CEO	Sell	10,000	$75.63	$756,300.00
4/10/2017	Andrew K. Balo	EVP	Sell	3,200	$78.19	$250,208.00
3/23/2017	Richard Doubleday	EVP	Sell	3,182	$76.38	$243,041.16
3/22/2017	Jess Roper	CFO	Sell	2,000	$75.97	$151,940.00
3/17/2017	Kevin R Sayer	CEO	Sell	10,000	$77.82	$778,200.00
3/14/2017	Jacob Steven Leach	SVP	Sell	21,317	$77.63	$1,654,838.71
3/13/2017	Jorge A. Valdes	Insider	Sell	14,400	$77.74	$1,119,456.00
3/9/2017	John Lister	Insider	Sell	3,000	$77.67	$233,010.00
3/6/2017	Jay S Skyler	Director	Sell	31,890	$78.13	$2,491,565.70
2/23/2017	Richard Doubleday	EVP	Sell	3,182	$78.42	$249,532.44
1/23/2017	Richard Doubleday	EVP	Sell	3,182	$79.50	$252,969.00
1/18/2017	Jess Roper	CFO	Sell	3,012	$85.01	$256,050.12
1/17/2017	Kevin R Sayer	CEO	Sell	10,000	$85.94	$859,400.00
1/13/2017	John Lister	Insider	Sell	15,000	$79.36	$1,190,400.00
1/10/2017	Andrew K Balo	EVP	Sell	3,200	$62.86	$201,152.00
1/9/2017	Jorge A Valdes	Insider	Sell	10,900	$63.02	$686,918.00
12/23/2016	Richard Doubleday	EVP	Sell	3,182	$62.17	$197,824.94
12/9/2016	Jorge A Valdes	Insider	Sell	10,000	$64.81	$648,100.00
10/24/2016	Jess Roper	CFO	Sell	2,471	$80.75	$199,533.25
10/24/2016	Steven Robert Pacelli	EVP	Sell	10,300	$81.95	$844,085.00
10/19/2016	Andrew K. Balo	EVP	Sell	4,997	$82.31	$411,303.07
10/14/2016	Kevin R. Sayer	CEO	Sell	7,000	$81.87	$573,090.00
10/10/2016	John Lister	Insider	Sell	3,560	$84.41	$300,499.60
10/5/2016	Andrew K. Balo	EVP	Sell	5,000	$82.55	$412,750.00
9/23/2016	Richard Doubleday	EVP	Sell	3,182	$93.97	$299,012.54
9/22/2016	Jess Roper	CFO	Sell	2,470	$93.99	$232,155.30
9/21/2016	Andrew K. Balo	EVP	Sell	5,000	$92.87	$464,350.00
9/14/2016	Kevin R. Sayer	CEO	Sell	7,000	$91.79	$642,530.00
9/12/2016	Jay S Skyler	Director	Sell	10,000	$93.00	$930,000.00
9/12/2016	Jorge A Valdes	Insider	Sell	19,071	$93.07	$1,774,937.97
9/9/2016	Jay S Skyler	Director	Sell	25,000	$94.07	$2,351,750.00
9/9/2016	John Lister	Insider	Sell	3,560	$93.65	$333,394.00
9/8/2016	Terrance H Gregg	Insider	Sell	10,740	$95.29	$1,023,414.60
9/7/2016	Andrew K Balo	EVP	Sell	4,999	$94.45	$472,155.55
9/7/2016	Mark G. Foletta	Director	Sell	1,800	$94.63	$170,334.00
9/1/2016	Jonathan T. Md Lord	Director	Sell	10,000	$91.50	$915,000.00
8/30/2016	Terrance H Gregg	Insider	Sell	10,000	$92.14	$921,400.00
8/24/2016	Andrew K Balo	EVP	Sell	5,000	$91.72	$458,600.00
8/24/2016	Terrance H Gregg	Insider	Sell	10,000	$92.72	$927,200.00
8/23/2016	Steven Robert Pacelli	EVP	Sell	10,300	$90.74	$934,622.00
8/23/2016	Terrance H Gregg	Chairman	Sell	10,000	$91.11	$911,100.00
8/22/2016	Terrance H Gregg	Chairman	Sell	10,000	$90.51	$905,100.00
8/19/2016	Jay S Skyler	Director	Sell	25,000	$90.77	$2,269,250.00
8/19/2016	Terrance H Gregg	Insider	Sell	40,000	$90.70	$3,628,000.00
8/15/2016	Kevin R. Sayer	CEO	Sell	7,000	$90.78	$635,460.00
8/15/2016	Terrance H Gregg	Chairman	Sell	14,942	$91.01	$1,359,871.42
8/12/2016	Jonathan T. Md Lord	Director	Sell	10,000	$90.64	$906,400.00
8/11/2016	Terrance H Gregg	Insider	Sell	10,900	$91.03	$992,227.00
8/10/2016	Andrew K Balo	EVP	Sell	5,000	$90.26	$451,300.00
8/9/2016	Jorge A Valdes	Insider	Sell	32,000	$91.06	$2,913,920.00
8/9/2016	Kevin R Sayer	CEO	Sell	20,000	$90.98	$1,819,600.00
8/8/2016	Barbara Kahn	Director	Sell	6,000	$90.52	$543,120.00
8/5/2016	Terrance H. Gregg	Insider	Sell	35,000	$79.81	$2,793,350.00
8/1/2016	Jeffrey Moy	SVP	Sell	15,000	$92.33	$1,384,950.00
7/27/2016	Andrew K Balo	EVP	Sell	5,000	$88.14	$440,700.00
7/25/2016	Richard Doubleday	EVP	Sell	3,182	$87.31	$277,820.42
7/22/2016	Jeffrey Moy	SVP	Sell	10,000	$88.48	$884,800.00
7/19/2016	Jeffrey Moy	SVP	Sell	12,843	$83.78	$1,075,986.54
7/13/2016	Andrew K Balo	EVP	Sell	5,000	$80.12	$400,600.00
7/13/2016	Kevin R. Sayer	CEO	Sell	7,000	$79.92	$559,440.00
7/11/2016	Jorge A Valdes	Insider	Sell	32,000	$79.36	$2,539,520.00
6/29/2016	Andrew K Balo	EVP	Sell	5,000	$78.10	$390,500.00
6/29/2016	Jeffrey Moy	SVP	Sell	4,557	$80.00	$364,560.00
6/23/2016	Steven Robert Pacelli	EVP	Sell	10,300	$77.40	$797,220.00
6/20/2016	Andrew K Balo	EVP	Sell	55,000	$75.00	$4,125,000.00
6/20/2016	Jeffrey Moy	SVP	Sell	7,209	$77.00	$555,093.00
6/20/2016	Kevin R. Sayer	CEO	Sell	35,000	$75.00	$2,625,000.00
6/9/2016	Jeffrey Moy	SVP	Sell	6,910	$74.00	$511,340.00
6/9/2016	John Lister	Insider	Sell	3,560	$73.27	$260,841.20
6/8/2016	Jeffrey Moy	SVP	Sell	6,866	$71.00	$487,486.00
6/8/2016	Jorge A Valdes	Insider	Sell	18,038	$72.06	$1,299,818.28
6/8/2016	Steven Robert Pacelli	EVP	Sell	18,239	$70.88	$1,292,780.32
6/7/2016	Jess Roper	CFO	Sell	3,471	$69.00	$239,499.00
5/23/2016	Richard Doubleday	EVP	Sell	1,674	$63.59	$106,449.66
5/18/2016	Jorge A Valdes	Insider	Sell	20,000	$61.75	$1,235,000.00
5/16/2016	Terrance H Gregg	Chairman	Sell	20,000	$62.72	$1,254,400.00
5/12/2016	Barbara Kahn	Director	Sell	3,000	$60.72	$182,160.00
5/11/2016	Terrance H Gregg	Chairman	Sell	8,600	$64.32	$553,152.00
5/9/2016	John Lister	Insider	Sell	3,560	$62.50	$222,500.00
5/9/2016	Terrance H Gregg	Chairman	Sell	12,168	$62.42	$759,526.56
4/27/2016	Jorge A Valdes	Insider	Sell	10,000	$70.00	$700,000.00
4/27/2016	Steven Robert Pacelli	EVP	Sell	2,361	$70.39	$166,190.79
4/25/2016	Jess Roper	CFO	Sell	3,471	$69.00	$239,499.00
4/25/2016	Richard Doubleday	EVP	Sell	1,666	$69.15	$115,203.90
4/12/2016	John Lister	Insider	Sell	3,704	$65.78	$243,649.12
4/11/2016	Terrance H Gregg	Chairman	Sell	2,169	$68.00	$147,492.00
4/4/2016	Jorge A Valdes	Insider	Sell	20,000	$70.08	$1,401,600.00
4/4/2016	Steven Robert Pacelli	EVP	Sell	20,600	$70.62	$1,454,772.00
3/31/2016	Jess Roper	CFO	Sell	3,470	$69.00	$239,430.00
3/23/2016	Richard Doubleday	EVP	Sell	1,666	$61.76	$102,892.16
3/22/2016	Terrance H Gregg	Chairman	Sell	25,000	$59.51	$1,487,750.00
3/14/2016	John Lister	Insider	Sell	3,560	$63.75	$226,950.00
3/7/2016	Barbara Kahn	Director	Sell	5,000	$67.04	$335,200.00
2/23/2016	Richard Doubleday	EVP	Sell	1,666	$64.36	$107,223.76
2/18/2016	John Lister	VP	Sell	3,560	$62.50	$222,500.00
1/25/2016	Steven Robert Pacelli	EVP	Sell	10,300	$73.24	$754,372.00
1/22/2016	Jess Roper	CFO	Sell	3,518	$72.97	$256,708.46
1/20/2016	Kevin R Sayer	CEO	Sell	7,000	$75.00	$525,000.00
1/12/2016	Jorge A Valdes	Insider	Sell	5,610	$80.16	$449,697.60
1/11/2016	Jorge A Valdes	Insider	Sell	1,641	$78.43	$128,703.63
1/8/2016	John Lister	VP	Sell	3,560	$82.57	$293,949.20
12/23/2015	Richard Doubleday	EVP	Sell	1,666	$82.22	$136,978.52
12/22/2015	Jess Roper	CFO	Sell	3,417	$81.19	$277,426.23
12/17/2015	Andrew K. Balo	EVP	Sell	7,500	$82.52	$618,900.00
12/14/2015	John Lister	VP	Sell	3,560	$82.50	$293,700.00
12/9/2015	Jorge A. Valdes	insider	Sell	10,000	$85.74	$857,400.00
12/8/2015	John Lister	VP	Sell	2,476	$87.16	$215,808.16
12/4/2015	Terrance H. Gregg	Chairman	Sell	10,000	$86.79	$867,900.00
12/3/2015	Andrew K. Balo	EVP	Sell	7,500	$86.37	$647,775.00
12/2/2015	Terrance H. Gregg	Chairman	Sell	10,000	$87.05	$870,500.00
11/30/2015	Terrance H. Gregg	Chairman	Sell	5,000	$86.50	$432,500.00
11/25/2015	Andrew K. Balo	EVP	Sell	7,500	$87.49	$656,175.00
11/25/2015	Terrance H. Gregg	Chairman	Sell	15,000	$87.53	$1,312,950.00
11/24/2015	Andrew K. Balo	EVP	Sell	10,000	$86.43	$864,300.00
11/24/2015	Terrance H. Gregg	Chairman	Sell	15,497	$86.54	$1,341,110.38
11/23/2015	Richard Doubleday	EVP	Sell	1,666	$85.85	$143,026.10
11/20/2015	Terrance H. Gregg	Chairman	Sell	22,003	$86.48	$1,902,819.44
11/18/2015	Jess Roper	CFO	Sell	7,000	$84.15	$589,050.00
11/16/2015	Terrance H. Gregg	Chairman	Sell	20,000	$83.89	$1,677,800.00
11/12/2015	Jess Roper	CFO	Sell	20,000	$84.07	$1,681,400.00
11/11/2015	Andrew K. Balo	EVP	Sell	7,500	$84.50	$633,750.00
10/23/2015	Richard Doubleday	EVP	Sell	1,666	$79.27	$132,063.82
10/20/2015	Andrew K Balo	EVP	Sell	4,538	$81.46	$369,665.48
10/19/2015	Jess Roper	CFO	Sell	7,000	$83.37	$583,590.00
10/15/2015	Terrance H Gregg	Chairman	Sell	15,000	$77.92	$1,168,800.00
10/6/2015	Andrew K Balo	EVP	Sell	8,216	$82.29	$676,094.64
9/23/2015	Steven Robert Pacelli	EVP	Sell	14,000	$98.08	$1,373,120.00
9/21/2015	Andrew K Balo	EVP	Sell	7,859	$100.72	$791,558.48
9/18/2015	Jess Roper	CFO	Sell	7,000	$101.22	$708,540.00
9/15/2015	Terrance H. Gregg	Chairman	Sell	29,999	$96.22	$2,886,503.78
9/11/2015	Terrance H. Gregg	Chairman	Sell	47,500	$96.50	$4,583,750.00
9/10/2015	Terrance H. Gregg	Chairman	Sell	62,501	$95.91	$5,994,470.91
9/9/2015	Jonathan T Md Lord	Director	Sell	10,000	$90.96	$909,600.00
9/8/2015	Andrew K Balo	EVP	Sell	7,500	$89.53	$671,475.00
9/8/2015	John Lister	VP	Sell	2,642	$89.36	$236,089.12
9/8/2015	Terrance H. Gregg	Chairman	Sell	25,000	$90.85	$2,271,250.00
9/1/2015	Jeffrey Moy	SVP	Sell	8,881	$90.61	$804,707.41
9/1/2015	Jorge A. Valdes	insider	Sell	20,000	$91.22	$1,824,400.00
8/28/2015	Steven Robert Pacelli	EVP	Sell	19,854	$94.67	$1,879,578.18
8/24/2015	Steven Robert Pacelli	EVP	Sell	14,000	$84.18	$1,178,520.00
8/20/2015	Andrew K Balo	EVP	Sell	7,500	$92.47	$693,525.00
8/18/2015	Steven R Altman	Director	Sell	5,000	$96.69	$483,450.00
8/17/2015	Jay S Skyler	Director	Sell	20,000	$96.65	$1,933,000.00
8/17/2015	Terrance H Gregg	Chairman	Sell	15,000	$96.71	$1,450,650.00
8/14/2015	Kevin R Sayer	CEO	Sell	35,000	$97.41	$3,409,350.00
7/23/2015	Richard Doubleday	EVP	Sell	9,641	$85.37	$823,052.17
7/22/2015	Andrew K Balo	EVP	Sell	10,214	$84.78	$865,942.92
7/21/2015	Jeffrey Moy	SVP	Sell	3,786	$83.48	$316,055.28
7/20/2015	Jess Roper	CFO	Sell	7,000	$83.74	$586,180.00
7/17/2015	Terrance H Gregg	Chairman	Sell	50,750	$83.07	$4,215,802.50
7/15/2015	Jay S Skyler	Director	Sell	20,000	$81.69	$1,633,800.00
7/8/2015	Andrew K Balo	EVP	Sell	4,494	$80.22	$360,508.68
7/8/2015	John Lister	VP	Sell	1,776	$79.94	$141,973.44
7/8/2015	Jorge A Valdes	Insider	Sell	50,000	$79.83	$3,991,500.00
7/7/2015	Jeffrey Moy	SVP	Sell	5,000	$79.32	$396,600.00
6/23/2015	Jeffrey Moy	SVP	Sell	5,154	$77.54	$399,641.16
6/23/2015	Steven Robert Pacelli	EVP	Sell	14,000	$77.53	$1,085,420.00
6/18/2015	Jess Roper	CFO	Sell	7,000	$77.10	$539,700.00
6/15/2015	Jay S Skyler	Director	Sell	20,000	$70.67	$1,413,400.00
6/15/2015	Terrance H Gregg	Chairman	Sell	15,000	$70.94	$1,064,100.00
6/12/2015	Terrance H. Gregg	Chairman	Sell	25,000	$72.30	$1,807,500.00
6/11/2015	Jeffrey Moy	SVP	Sell	9,869	$73.00	$720,437.00
6/9/2015	Andrew K Balo	EVP	Sell	7,500	$70.62	$529,650.00
6/9/2015	Jeffrey Moy	SVP	Sell	5,000	$70.63	$353,150.00
6/9/2015	Jorge A Valdes	Insider	Sell	19,680	$71.32	$1,403,577.60
6/8/2015	John Lister	VP	Sell	1,776	$72.03	$127,925.28
6/8/2015	Jorge A Valdes	Insider	Sell	8,243	$72.07	$594,073.01
6/3/2015	Terrance H Gregg	Chairman	Sell	40,000	$72.77	$2,910,800.00
6/2/2015	Terrance H Gregg	Chairman	Sell	5,000	$73.12	$365,600.00
6/1/2015	Terrance H Gregg	Chairman	Sell	10,000	$72.75	$727,500.00
5/27/2015	Jeffrey Moy	SVP	Sell	21,791	$69.60	$1,516,653.60
5/27/2015	Richard Doubleday	EVP	Sell	3,258	$70.73	$230,438.34
5/18/2015	Andrew K Balo	EVP	Sell	7,500	$68.46	$513,450.00
5/18/2015	Jeffrey Moy	SVP	Sell	15,586	$69.20	$1,078,551.20
5/18/2015	Jess Roper	CFO	Sell	7,000	$69.27	$484,890.00
5/15/2015	Terrance H Gregg	Chairman	Sell	82,500	$69.24	$5,712,300.00
5/12/2015	Jeffrey Moy	SVP	Sell	20,303	$67.84	$1,377,355.52
5/12/2015	Jorge A Valdes	Insider	Sell	30,878	$68.27	$2,108,041.06
5/11/2015	Jeffrey Moy	SVP	Sell	15,303	$68.25	$1,044,429.75
5/11/2015	Terrance H Gregg	Chairman	Sell	3,517	$68.65	$241,442.05
5/8/2015	Terrance H Gregg	Chairman	Sell	91,483	$67.85	$6,207,121.55
5/4/2015	Kevin R Sayer	CEO	Sell	25,000	$68.01	$1,700,250.00
4/28/2015	Jeffrey Moy	SVP	Sell	10,000	$68.41	$684,100.00
4/27/2015	Jeffrey Moy	SVP	Sell	5,000	$69.27	$346,350.00
4/23/2015	Steven Robert Pacelli	EVP	Sell	39,709	$69.63	$2,764,937.67
4/20/2015	Jess Roper	CFO	Sell	7,000	$68.05	$476,350.00
4/15/2015	Terrance H Gregg	Chairman	Sell	15,000	$67.56	$1,013,400.00
4/14/2015	Jeffrey Moy	SVP	Sell	20,766	$66.63	$1,383,638.58
4/9/2015	Andrew K Balo	EVP	Sell	7,500	$64.55	$484,125.00
4/9/2015	Jorge A Valdes	Insider	Sell	19,684	$64.38	$1,267,255.92
4/8/2015	John Lister	VP	Sell	5,039	$63.84	$321,689.76
3/25/2015	Andrew K Balo	EVP	Sell	7,500	$61.05	$457,875.00
3/23/2015	Steven Robert Pacelli	EVP	Sell	14,000	$61.33	$858,620.00
3/18/2015	Jess Roper	CFO	Sell	7,000	$62.43	$437,010.00
3/17/2015	Terrance H Gregg	Chairman	Sell	15,000	$62.82	$942,300.00
3/13/2015	Jay S Skyler	Director	Sell	45,000	$60.01	$2,700,450.00
3/12/2015	Jorge A Valdes	Insider	Sell	11,138	$59.78	$665,829.64
3/12/2015	Richard Doubleday	EVP	Sell	20,000	$59.23	$1,184,600.00
3/9/2015	John Lister	VP	Sell	5,039	$58.77	$296,142.03
3/9/2015	Jorge A Valdes	Insider	Sell	8,244	$58.77	$484,499.88
2/23/2015	Richard Doubleday	EVP	Sell	4,000	$63.58	$254,320.00
2/9/2015	John Lister	VP	Sell	5,039	$61.66	$310,704.74
2/9/2015	Jorge A Valdes	Insider	Sell	8,244	$61.67	$508,407.48
2/2/2015	Jeffrey Moy	SVP	Sell	5,000	$60.69	$303,450.00
1/26/2015	Steven Robert Pacelli	EVP	Sell	24,532	$59.67	$1,463,824.44
1/23/2015	Richard Doubleday	EVP	Sell	4,000	$58.22	$232,880.00
1/20/2015	Jeffrey Moy	SVP	Sell	5,000	$57.58	$287,900.00
1/20/2015	Jess Roper	CFO	Sell	7,000	$57.34	$401,380.00
1/15/2015	Terrance H Gregg	Chairman	Sell	15,000	$57.84	$867,600.00
1/13/2015	Steven Robert Pacelli	EVP	Sell	9,468	$62.22	$589,098.96
1/12/2015	Steven Robert Pacelli	EVP	Sell	20,000	$59.18	$1,183,600.00
1/9/2015	Jorge A Valdes	Insider	Sell	9,170	$57.55	$527,733.50
1/8/2015	John Lister	VP	Sell	5,039	$57.42	$289,339.38
1/5/2015	Jeffrey Moy	SVP	Sell	5,000	$55.27	$276,350.00
12/26/2014	Andrew K Balo	SVP	Sell	10,000	$55.27	$552,700.00
12/23/2014	Richard Doubleday	VP	Sell	4,000	$54.69	$218,760.00
12/23/2014	Steven Robert Pacelli	EVP	Sell	14,000	$54.62	$764,680.00
12/18/2014	Jess Roper	CFO	Sell	12,000	$56.43	$677,160.00
12/15/2014	Terrance H Gregg	CEO	Sell	35,000	$53.23	$1,863,050.00
12/8/2014	Jorge A Valdes	Insider	Sell	16,000	$56.03	$896,480.00
12/3/2014	Eric Topol	Director	Sell	20,000	$55.00	$1,100,000.00
11/28/2014	Terrance H Gregg	CEO	Sell	59,990	$51.51	$3,090,084.90
11/25/2014	Andrew K Balo	SVP	Sell	10,000	$51.11	$511,100.00
11/25/2014	Terrance H Gregg	CEO	Sell	55,010	$51.04	$2,807,710.40
11/24/2014	Richard Doubleday	VP	Sell	4,000	$50.36	$201,440.00
11/24/2014	Terrance H Gregg	CEO	Sell	35,000	$51.06	$1,787,100.00
11/21/2014	Terrance H Gregg	CEO	Sell	10,000	$50.50	$505,000.00
11/19/2014	Terrance H Gregg	CEO	Sell	10,000	$51.00	$510,000.00
11/17/2014	Terrance H Gregg	CEO	Sell	45,000	$52.52	$2,363,400.00
11/12/2014	Terrance H Gregg	CEO	Sell	80,000	$53.36	$4,268,800.00
11/10/2014	Jorge A Valdes	Insider	Sell	16,000	$51.23	$819,680.00
10/27/2014	Andrew K Balo	SVP	Sell	10,000	$42.98	$429,800.00
10/23/2014	Richard Doubleday	VP	Sell	4,000	$43.58	$174,320.00
10/23/2014	Steven Robert Pacelli	EVP	Sell	14,000	$43.60	$610,400.00
10/13/2014	Andrew K Balo	SVP	Sell	10,000	$40.42	$404,200.00
10/13/2014	John Lister	VP	Sell	3,400	$40.41	$137,394.00
10/8/2014	Jorge A Valdes	Insider	Sell	16,000	$40.29	$644,640.00
9/25/2014	Andrew K Balo	SVP	Sell	10,000	$40.71	$407,100.00
9/23/2014	Richard Doubleday	VP	Sell	4,000	$40.32	$161,280.00
9/23/2014	Steven Robert Pacelli	EVP	Sell	14,000	$40.32	$564,480.00
9/18/2014	Jess Roper	CFO	Sell	8,000	$41.91	$335,280.00
9/15/2014	Terrance H Gregg	CEO	Sell	35,000	$41.14	$1,439,900.00
9/12/2014	John Lister	VP	Sell	3,518	$43.70	$153,736.60
9/11/2014	Andrew K Balo	SVP	Sell	10,000	$42.97	$429,700.00
9/8/2014	Jorge A Valdes	Insider	Sell	16,000	$42.98	$687,680.00
8/28/2014	Barbara Kahn	Director	Sell	4,000	$44.52	$178,080.00
8/26/2014	Jeffrey Moy	SVP	Sell	16,663	$45.30	$754,833.90
8/26/2014	Jonathan T Md Lord	Director	Sell	20,000	$45.56	$911,200.00
8/26/2014	Steven Robert Pacelli	EVP	Sell	30,000	$44.56	$1,336,800.00
8/26/2014	Terrance H Gregg	CEO	Sell	5,000	$46.05	$230,250.00
8/25/2014	Andrew K Balo	SVP	Sell	10,000	$44.12	$441,200.00
8/25/2014	Richard Doubleday	VP	Sell	4,000	$44.35	$177,400.00
8/25/2014	Steven Robert Pacelli	EVP	Sell	14,000	$44.24	$619,360.00
8/22/2014	Andrew K Balo	SVP	Sell	20,000	$44.24	$884,800.00
8/22/2014	Terrance H Gregg	CEO	Sell	13,607	$44.46	$604,967.22
8/21/2014	Barbara Kahn	Director	Sell	2,200	$43.42	$95,524.00
8/21/2014	Jorge A Valdes	Insider	Sell	10,671	$43.58	$465,042.18
8/21/2014	Terrance H Gregg	CEO	Sell	23,893	$44.36	$1,059,893.48
8/19/2014	Richard Doubleday	VP	Sell	20,000	$45.01	$900,200.00
8/19/2014	Terrance H Gregg	CEO	Sell	75,000	$45.08	$3,381,000.00
8/18/2014	Terrance H Gregg	CEO	Sell	65,000	$44.16	$2,870,400.00
8/14/2014	Terrance H Gregg	CEO	Sell	25,000	$44.24	$1,106,000.00
8/13/2014	Terrance H Gregg	CEO	Sell	56,107	$43.57	$2,444,581.99
8/11/2014	Andrew K Balo	SVP	Sell	10,000	$44.24	$442,400.00
8/11/2014	Kevin R Sayer	COO	Sell	20,000	$43.82	$876,400.00
8/8/2014	Jorge A Valdes	Insider	Sell	16,000	$43.56	$696,960.00
7/25/2014	Andrew K Balo	SVP	Sell	10,000	$38.19	$381,900.00
7/23/2014	Richard Doubleday	VP	Sell	4,000	$38.16	$152,640.00
7/23/2014	Steven Robert Pacelli	EVP	Sell	14,000	$38.28	$535,920.00
7/18/2014	Jess Roper	CFO	Sell	8,000	$36.01	$288,080.00
7/15/2014	Terrance H Gregg	CEO	Sell	35,000	$36.66	$1,283,100.00
7/14/2014	John Lister	VP	Sell	3,500	$36.59	$128,065.00
7/11/2014	Andrew K Balo	SVP	Sell	10,000	$35.93	$359,300.00
7/8/2014	Jorge A Valdes	Insider	Sell	16,000	$36.66	$586,560.00
7/2/2014	Jay S Skyler	Director	Sell	30,000	$40.05	$1,201,500.00
6/25/2014	Andrew K Balo	SVP	Sell	10,000	$40.60	$406,000.00
6/23/2014	Richard Doubleday	VP	Sell	4,000	$40.98	$163,920.00
6/23/2014	Steven Robert Pacelli	EVP	Sell	14,000	$41.02	$574,280.00
6/20/2014	Jay S Skyler	Director	Sell	60,000	$40.00	$2,400,000.00
6/18/2014	Jess Roper	CFO	Sell	8,000	$39.17	$313,360.00
6/16/2014	Terrance H Gregg	CEO	Sell	35,000	$37.23	$1,303,050.00
6/12/2014	John Lister	VP	Sell	3,500	$36.13	$126,455.00
6/11/2014	Andrew K Balo	SVP	Sell	10,000	$36.63	$366,300.00
6/9/2014	Jorge A Valdes	Insider	Sell	16,000	$36.68	$586,880.00
6/5/2014	Richard Doubleday	VP	Sell	4,000	$35.59	$142,360.00
5/27/2014	Andrew K Balo	SVP	Sell	10,000	$33.86	$338,600.00
5/19/2014	Jess Roper	CFO	Sell	8,000	$32.20	$257,600.00
5/8/2014	Jorge Valdes	Insider	Sell	16,000	$29.83	$477,280.00
4/25/2014	Andrew Balo	SVP	Sell	10,000	$34.35	$343,500.00
4/23/2014	Richard Doubleday	VP	Sell	4,000	$35.92	$143,680.00
4/23/2014	Steven Robert Pacelli	EVP	Sell	14,000	$35.90	$502,600.00
4/21/2014	Jess Roper	CFO	Sell	8,000	$36.18	$289,440.00
4/15/2014	Terrance Gregg	CEO	Sell	35,000	$34.09	$1,193,150.00
4/14/2014	John Lister	VP	Sell	2,884	$35.86	$103,420.24
4/11/2014	Andrew Balo	SVP	Sell	10,000	$35.36	$353,600.00
4/8/2014	Jorge Valdes	Insider	Sell	16,000	$35.99	$575,840.00
3/26/2014	Jay Skyler	Director	Sell	30,000	$43.05	$1,291,500.00
3/25/2014	Andrew Balo	SVP	Sell	10,000	$43.00	$430,000.00
3/24/2014	Steven Robert Pacelli	EVP	Sell	14,000	$42.92	$600,880.00
3/18/2014	Jess Roper	CFO	Sell	8,000	$46.00	$368,000.00
3/17/2014	Terrance Gregg	CEO	Sell	45,000	$45.25	$2,036,250.00
3/12/2014	Terrance Gregg	CEO	Sell	30,000	$45.50	$1,365,000.00
3/10/2014	Jorge Valdes	Insider	Sell	16,000	$46.57	$745,120.00
3/5/2014	Jeffrey Moy	SVP	Sell	10,000	$47.30	$473,000.00
3/5/2014	Terrance Gregg	CEO	Sell	111,890	$47.46	$5,310,299.40
3/3/2014	Terrance Gregg	CEO	Sell	40,000	$44.87	$1,794,800.00
2/26/2014	Jess Roper	CFO	Sell	25,000	$45.20	$1,130,000.00
2/25/2014	Steven Robert Pacelli	EVP	Sell	33,368	$44.93	$1,499,224.24
1/23/2014	Steven Robert Pacelli	EVP	Sell	14,000	$36.49	$510,860.00
1/21/2014	Jess Roper	CFO	Sell	8,000	$37.38	$299,040.00
12/18/2013	Jess Roper	CFO	Sell	8,000	$34.48	$275,840.00
12/13/2013	Terrance Gregg	CEO	Sell	50,000	$34.41	$1,720,500.00
12/12/2013	Nicholas Augustinos	Director	Sell	11,321	$34.40	$389,442.40
12/10/2013	Nicholas Augustinos	Director	Sell	97,541	$33.64	$3,281,279.24
12/5/2013	Terrance Gregg	CEO	Sell	20,000	$34.77	$695,400.00
12/3/2013	Andrew Balo	SVP	Sell	14,268	$34.21	$488,108.28
11/15/2013	Terrance Gregg	CEO	Sell	35,000	$32.74	$1,145,900.00
9/3/2013	Terrance Gregg	CEO	Sell	9,000	$27.00	$243,000.00
8/1/2013	Terrance H Gregg	CEO	Sell	9,000	$22.15	$199,350.00
7/1/2013	Terrance H Gregg	CEO	Sell	9,000	$22.87	$205,830.00
6/13/2013	Andrew K Balo	SVP	Sell	10,000	$21.90	$219,000.00
6/11/2013	Jess Roper	CFO	Sell	10,361	$22.33	$231,361.13
6/11/2013	John Lister	VP	Sell	2,000	$22.43	$44,860.00
6/11/2013	Steven Robert Pacelli	EVP	Sell	5,000	$22.31	$111,550.00
6/4/2013	Terrance H Gregg	CEO	Sell	19,000	$21.32	$405,080.00
5/15/2013	Jeffrey Moy	SVP	Sell	5,000	$19.97	$99,850.00
5/13/2013	Andrew K Balo	SVP	Sell	45,000	$19.40	$873,000.00
5/9/2013	Richard Doubleday	SVP	Sell	1,272	$19.56	$24,880.32
3/13/2013	Andrew K Balo	SVP	Sell	15,416	$16.53	$254,826.48
3/11/2013	Jay S Skyler	Director	Buy	70,000	$15.50	$1,085,000.00
3/11/2013	John Lister	VP	Sell	4,500	$15.75	$70,875.00
3/11/2013	Richard Doubleday	SVP	Sell	5,100	$15.63	$79,713.00
2/1/2013	Terrance H Gregg	CEO	Sell	9,000	$15.08	$135,720.00
12/3/2012	Terrance H Gregg	CEO	Sell	5,000	$13.24	$66,200.00
9/4/2012	Terrance H Gregg	CEO	Sell	15,000	$13.46	$201,900.00

(Data available from 1/1/2013 forward)

Headline Trends for DexCom (NASDAQ:DXCM) Latest Headlines for DexCom (NASDAQ:DXCM)

Source:

Date	Headline
	DexCom Announces Upcoming Conference Presentation finance.yahoo.com - October 19 at 6:40 PM
	ETFs with exposure to DexCom, Inc. : October 17, 2017 finance.yahoo.com - October 17 at 6:48 PM
	DexCom, Inc. (DXCM) Downgraded by Zacks Investment Research www.americanbankingnews.com - October 17 at 3:32 PM
	Head to Head Comparison: CONMED Corporation (CNMD) vs. DexCom (DXCM) www.americanbankingnews.com - October 17 at 10:34 AM
	$183.55 Million in Sales Expected for DexCom, Inc. (DXCM) This Quarter www.americanbankingnews.com - October 17 at 3:42 AM
	Brokerages Anticipate DexCom, Inc. (DXCM) Will Announce Earnings of -$0.15 Per Share www.americanbankingnews.com - October 15 at 4:08 PM
	DexCom Schedules Third Quarter 2017 Earnings Release and Conference Call for November 1, 2017 at 4:30 p.m. Eastern Time finance.yahoo.com - October 10 at 8:52 PM
	DexCom's Quiet Consolidation After Huge Decline - Benzinga www.benzinga.com - October 10 at 6:14 AM
	Head to Head Analysis: DexCom (DXCM) and Transenterix (TRXC) www.americanbankingnews.com - October 9 at 8:28 PM
	DexCom's Quiet Consolidation After Huge Decline finance.yahoo.com - October 9 at 6:28 PM
	DexCom, Inc. (DXCM) Receives Average Recommendation of "Buy" from Analysts www.americanbankingnews.com - October 7 at 7:36 AM
	ETFs with exposure to DexCom, Inc. : October 6, 2017 finance.yahoo.com - October 6 at 6:26 PM
	Cramer Remix: My mea culpa on DexCom and where it's headed - CNBC www.cnbc.com - October 5 at 10:01 AM
	DexCom, Inc. :DXCM-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017 finance.yahoo.com - October 5 at 10:01 AM
	Wedbush Reiterates "Buy" Rating for DexCom, Inc. (DXCM) www.americanbankingnews.com - October 4 at 11:44 PM
	How Wall Street Reacted to the FDA Approval of Abbott’s Freestyle Libre finance.yahoo.com - October 3 at 9:31 AM
	DexCom, Inc. to Post Q4 2018 Earnings of $0.00 Per Share, Leerink Swann Forecasts (DXCM) www.americanbankingnews.com - October 2 at 9:32 AM
	Oppenheimer Holdings Equities Analysts Decrease Earnings Estimates for DexCom, Inc. (DXCM) www.americanbankingnews.com - October 2 at 4:08 AM
	DexCom, Inc. (DXCM) Receives New Coverage from Analysts at Northland Securities www.americanbankingnews.com - October 1 at 11:34 PM
	DexCom, Inc. (DXCM) Rating Lowered to Neutral at J P Morgan Chase & Co www.americanbankingnews.com - September 30 at 12:28 PM
	DexCom, Inc. (DXCM) Downgraded to Mkt Perform at Raymond James Financial, Inc. www.americanbankingnews.com - September 29 at 11:08 PM
	DexCom's (DXCM) Buy Rating Reaffirmed at Leerink Swann www.americanbankingnews.com - September 29 at 6:00 PM
	Canaccord Sticks With Dexcom As Shares Tumble Amid Unexpected Label Addition finance.yahoo.com - September 29 at 2:14 PM
	DexCom, Inc. (DXCM) Expected to Post Q4 2017 Earnings of $0.06 Per Share www.americanbankingnews.com - September 29 at 8:26 AM
	Citigroup Inc. Downgrades DexCom, Inc. (DXCM) to Market Perform www.americanbankingnews.com - September 28 at 8:56 PM
	Jefferies Group LLC Reaffirms "Buy" Rating for DexCom, Inc. (DXCM) www.americanbankingnews.com - September 28 at 7:34 PM
	Pre-Market Most Active for Sep 28, 2017 : ERIC, ZYNE, RAD, BBRY, DXCM, EXA, ITCI, DB, SAN, TEVA, NKE, BAC - Nasdaq www.nasdaq.com - September 28 at 6:20 PM
	Canaccord Sticks With Dexcom As Shares Tumble Amid Unexpected Label Addition - Benzinga www.benzinga.com - September 28 at 6:20 PM
	DexCom, Inc. (DXCM) Price Target Cut to $60.00 by Analysts at Barclays PLC www.americanbankingnews.com - September 28 at 5:38 PM
	DexCom, Inc. (DXCM) Receives Buy Rating from Stephens www.americanbankingnews.com - September 28 at 3:40 PM
	DexCom, Inc. (DXCM) Receives "Buy" Rating from Piper Jaffray Companies www.americanbankingnews.com - September 28 at 3:12 PM
	DexCom, Inc. (DXCM) PT Lowered to $64.00 www.americanbankingnews.com - September 28 at 1:48 PM
	DexCom's (DXCM) Outperform Rating Reiterated at BMO Capital Markets www.americanbankingnews.com - September 28 at 1:48 PM
	Noteworthy Thursday Option Activity: DXCM, AQMS, TCX www.thestreet.com - September 28 at 1:18 PM
	DexCom Becomes Oversold (DXCM) www.nasdaq.com - September 28 at 1:18 PM
	Why DexCom Stock Is Getting Crushed Today www.fool.com - September 28 at 1:06 PM
	Abbott shares jump after approval for diabetes monitor; competitor DexCom crashes on surprise news www.cnbc.com - September 28 at 1:05 PM
	Oppenheimer Holdings, Inc. Lowers DexCom, Inc. (DXCM) Price Target to $85.00 www.americanbankingnews.com - September 28 at 12:34 PM
	Robert W. Baird Lowers DexCom, Inc. (DXCM) Price Target to $58.00 www.americanbankingnews.com - September 28 at 10:54 AM
	Northland Securities Downgrades DexCom, Inc. (DXCM) to Market Perform www.americanbankingnews.com - September 28 at 10:28 AM
	DexCom, Inc. (DXCM) Stock Rating Reaffirmed by Raymond James Financial, Inc. www.americanbankingnews.com - September 28 at 8:48 AM
	DexCom, Inc. (DXCM) Receives Buy Rating from Canaccord Genuity www.americanbankingnews.com - September 28 at 8:48 AM
	DexCom's (DXCM) "Outperform" Rating Reiterated at Wedbush www.americanbankingnews.com - September 28 at 8:18 AM
	$183.65 Million in Sales Expected for DexCom, Inc. (DXCM) This Quarter www.americanbankingnews.com - September 28 at 3:56 AM
	DexCom, Inc. (DXCM) EVP Steven Robert Pacelli Sells 1,450 Shares www.americanbankingnews.com - September 27 at 10:32 PM
	-$0.14 Earnings Per Share Expected for DexCom, Inc. (DXCM) This Quarter www.americanbankingnews.com - September 27 at 12:32 AM
	Insider Selling: DexCom, Inc. (DXCM) CEO Sells 6,000 Shares of Stock www.americanbankingnews.com - September 22 at 7:52 PM
	DexCom Opens Data Platform and Launches Developer Program to ... - Business Wire (press release) www.businesswire.com - September 19 at 6:02 PM
	DexCom, Inc. (DXCM) Earns Equal Weight Rating from Analysts at Barclays PLC www.americanbankingnews.com - September 16 at 12:26 AM
	Insider Selling: DexCom, Inc. (DXCM) EVP Sells 3,244 Shares of Stock www.americanbankingnews.com - September 13 at 8:28 PM